데이터가 없습니다.

1. Association of cyclooxygenase-2 expression with endoplasmic reticulum stress and autophagy in triple-negative breast cancer [ PLoS One ] - 2023.08.04
2. Tumor-infiltrating lymphocyte therapy: Clinical aspects and future developments in this breakthrough cancer treatment [ BIOESSAYS ] - 2023.07.01
3. Immune repertoire and responses to neoadjuvant TCHP therapy in HER2-positive breast cancer [ Therapeutic advances in Medical Oncology ] - 2023.02.27
4. Establishing Patient-Derived Cancer Cell Cultures and Xenografts in Biliary Tract Cancer [ CANCER RESEARCH AND TREATMENT ] - 2023.01.15
5. The Association of Estrogen Receptor Activity, Interferon Signaling, and MHC Class I Expression in Breast Cancer [ CANCER RESEARCH AND TREATMENT ] - 2022.10.01
6. Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer [ BMC CANCER ] - 2022.09.24
7. Phenotypic Differences of CD103+ Tissue-Resident Memory T Cells Associated with Various Cancers [ PATHOBIOLOGY ] - 2022.03.01
8. A DNA Topoisomerase II Inhibitor Results in Ex Vivo Differentiation of THP-1 Cells and Activation of Dendritic Cells [ ANTICANCER RESEARCH ] - 2021.12.01
9. A New Human Leukocyte Antigen Typing Algorithm Combined With Currently Available Genotyping Tools Based on Next-Generation Sequencing Data and Guidelines to Select the Most Likely Human Leukocyte Antigen Genotype [ FRONTIERS IN IMMUNOLOGY ] - 2021.10.01
10. Clinicopathological factors associated with tumor-infiltrating lymphocyte reactivity in breast cancer [ CANCER IMMUNOLOGY IMMUNOTHERAPY ] - 2020.11.01
11. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients [ IMMUNOLOGIC RESEARCH ] - 2020.10.01
12. Changes in Tumor-infiltrating Lymphocytes After Neoadjuvant Chemotherapy and Clinical Significance in Triple Negative Breast Cancer [ ANTICANCER RESEARCH ] - 2020.04.01
13. Retained or altered expression of major histocompatibility complex class I in patient-derived xenograft models in breast cancer [ IMMUNOLOGIC RESEARCH ] - 2019.12.01
14. Association between p53 Expression and Amount of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer [ Journal of Pathology and Translational Medicine ] - 2019.05.01
15. Presence of tertiary lymphoid structures determines the level of tumor-infiltrating lymphocytes in primary breast cancer and metastasis [ MODERN PATHOLOGY ] - 2019.01.01
16. Expression of Immunoproteasome Subunit LMP7 in Breast Cancer and Its Association with Immune-Related Markers [ CANCER RESEARCH AND TREATMENT ] - 2019.01.01
17. Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer [ ONCOTARGET ] - 2017.12.26
18. ADAR1 expression is associated with tumour-infiltrating lymphocytes in triple-negative breast cancer. [ TUMOR BIOLOGY ] - 2017.10.01
19. Expression of the MHC class II in triple-negative breast cancer is associated with tumor-infiltrating lymphocytes and interferon signaling [ PLOS ONE ] - 2017.08.17
20. Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer [ CANCER RESEARCH AND TREATMENT ] - 2017.04.01
21. Glutaminase expression is a poor prognostic factor in node-positive triple-negative breast cancer patients with a high level of tumor-infiltrating lymphocytes [ VIRCHOWS ARCHIV ] - 2017.04.01
22. Endoplasmic reticulum stress induces secretion of high-mobility group proteins and is associated with tumor-infiltrating lymphocytes in triple-negative breast cancer [ Oncotarget ] - 2016.09.13
23. An Examination of the Local Cellular Immune Response to Examples of Both Ductal Carcinoma In Situ (DCIS) of the Breast and DCIS With Microinvasion, With Emphasis on Tertiary Lymphoid Structures and Tumor Infiltrating Lymphoctytes [ AMERICAN JOURNAL OF CLINICAL PATHOLOGY ] - 2016.07.01
24. Activation of the PERK-eIF2 alpha Pathway Is Associated with Tumor-infiltrating Lymphocytes in HER2-Positive Breast Cancer [ ANTICANCER RESEARCH ] - 2016.06.01
25. Differential expression of major histocompatibility complex class I in subtypes of breast cancer is associated with estrogen receptor and interferon signaling [ Oncotarget ] - 2016.05.24
26. MxA expression is associated with tumor-infiltrating lymphocytes and is a prognostic factor in triple-negative breast cancer [ BREAST CANCER RESEARCH AND TREATMENT ] - 2016.04.13
27. Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer. [ PATHOLOGY INTERNATIONAL ] - 2016.04.01

1. 탈분화를 통한 중심 기억 T 세포 유도 - 2022.03.01 ~ 2023.02.28
2. 개인화된 다중표적 항암 면역세포 개발 - 2021.07.01 ~ 2022.11.30
3. (2021, 기본) 탈분화를 통한 중심 기억 T 세포 유도 - 2021.06.01 ~ 2022.02.28
4. 종양에 침윤한 B 림프구의 유전체 분석 및 기능 연구 - 2021.03.01 ~ 2021.05.31
5. HLA peptidome 분석을 통한 항암 백신 개발 연구 - 2021.01.01 ~ 2021.12.31
6. IHC를 이용한 삼중음성 유방암 환자 완전 관해 재발 예측 시스템 개발 - 2021.01.01 ~ 2021.12.31
7. 개인화된 다중표적 항암 면역세포 개발 - 2020.07.01 ~ 2021.06.30
8. 종양에 침윤한 B 림프구의 유전체 분석 및 기능 연구 - 2020.03.01 ~ 2021.02.28
9. HLA peptidome 분석을 통한 항암 백신 개발 연구 - 2020.01.01 ~ 2020.12.31
10. IHC를 이용한 삼중음성 유방암 환자 완전 관해/재발 예측 시스템 개발 - 2020.01.01 ~ 2020.12.31
11. 알고리즘을 이용해 예측된 신생항원의 면역원성 연구 - 2019.11.14 ~ 2020.06.30
12. 암 면역세포치료제의 효능 증진을 위한 종양항원 특이적 T 세포 마커 발굴 - 2019.10.01 ~ 2020.12.31
13. 개인화된 다중표적 항암 면역세포 개발 - 2019.07.01 ~ 2020.06.30
14. 항암 T 세포 치료제 개발 네오젠TC (neoantigen-specific T cell) - 2019.06.01 ~ 2019.09.30
15. 종양에 침윤한 B 림프구의 유전체 분석 및 기능 연구 - 2019.03.01 ~ 2020.02.29
16. 3차원 세포배양을 이용한 항암제 감수성 분석 - 2019.02.13 ~ 2029.12.31
17. T 세포 내 도입할 유전자 선별 및 유전자 변형 T 세포 효능 평가 - 2019.01.01 ~ 2019.12.31
18. HLA peptidome 분석을 통한 항암 백신 개발 연구 - 2019.01.01 ~ 2019.12.31
19. 개인화된 다중표적 항암 면역세포 개발 - 2018.10.01 ~ 2019.06.30
20. 종양에 침윤한 B 림프구의 유전체 분석 및 기능 연구 - 2018.06.01 ~ 2019.02.28
21. 네오젠TC (neoantigen-reactive T cell) Bio-SPC 설립 - 2018.05.01 ~ 2018.07.31
22. T 세포 내 도입할 유전자 선별 및 유전자 변형 T 세포 효능 평가 - 2018.01.01 ~ 2018.12.31
23. 유방암 환자의 종양 침윤 림프구를 이용한 개인 맞춤 면역 치료 - 2017.07.01 ~ 2018.06.30
24. T 세포 내 도입할 유전자 선별 및 유전자 변형 T 세포 효능 평가 - 2017.04.10 ~ 2017.12.31
25. 유방암 환자의 종양 침윤 림프구를 이용한 개인 맞춤 면역 치료 - 2016.07.01 ~ 2017.06.30

1. 인간 백혈구 항원의 타입 결정 방법 및 이를 통한 의료 개인화 방법 - 2023.03.02
2. 인간 백혈구 항원 A02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 - 2021.12.01
3. 인간 백혈구 항원 A24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 - 2021.11.01
4. 수지상세포로의 분화 유도용 조성물 - 2021.06.02
5. 면역유전자 차등발현 예측 모델을 이용한 유방암 환자에 대한 완전 관해 예측 방법 - 2020.11.27
6. 면역유전자 차등발현 예측 모델을 이용한 유방암 환자에 대한 재발 예측 방법 - 2020.11.27

      데이터가 없습니다.

 공지